Third Quarter Earnings Call - AMPHASTAR PHARMACEUTICALS INC

Financial Performance:

• Third quarter revenue reached a record $207.6 million, an 8% increase year-over-year and 13% sequentially.
• Gross margin declined to 48% from 51% in the prior year period, driven by lower net pricing on Baximi, Glucagon, and Epinephrine, alongside higher manufacturing expenses.
• Net income increased to $37.8 million ($0.87 per share) from $17.4 million ($0.37 per share) in the prior year; adjusted net income rose to $49.3 million ($1.14 per share).
• Cash flow from operations was $43.3 million; the Board authorized an additional $50 million for share buybacks.
• Revenue growth was driven by Vaccini ($58.8M, +10%), Primatine Mist ($31.5M, +9%), Lidocaine ($16.6M, +29% due to supplier shortages), and recent launches like Ipratropium ($6.6M) and Teriparatide ($6.4M).
• Headwinds included a 19% drop in Epinephrine sales ($15.3M) and a 37% drop in Glucagon sales ($8.6M) due to remediation at the IMS facility and increased competition, respectively.
• Operating expenses: G&A decreased 57% to $16.8M due to a prior-year legal settlement; R&D decreased 10% to $20.1M excluding one-time licensing payments.

Guidance and Future Outlook:

• Management expects fourth-quarter sales to grow in the high single-digit range compared to the prior year, incorporating a modest slowdown in IMS sales to prioritize quality remediation.
• The IMS facility is projected to return to full capacity around mid-2027, with remediation-related expenses expected to remain elevated ($2-$3M per quarter) through the next 2-3 quarters.
• Commercial growth for 2027 is anticipated to be supported by Baximi, Primatine Mist, and the annualized sales of Ipratropium, though 2027 EPS guidance has not been provided.
• The Aspart insulin biosimilar remains on track for a potential commercial launch in 2027, subject to FDA approval, despite a competitive landscape with existing generics.
• Proprietary programs aim for AMP108 filing by end of 2028 to maintain IP protection for Primatine Mist against regulatory changes.

Business Segments and Product Lines:

• Vaccini: Delivered record sales driven by volume growth from marketing efforts; duplicate 340B discount issues remain a pricing headwind but have improved significantly quarter-over-quarter.
• Primatine Mist: Achieved record sales driven by a Q2 price increase and higher in-store unit volumes (+2.5% YoY).
• Biosimilars: The insulin aspart biosimilar program is advancing with manufacturing and clinical activities; the GLP-1 generic is expected to face significant competition and is viewed as a limited opportunity.
• Proprietary Pipeline: AMP101 (intranasal epinephrine) progressed through Phase I with refined study designs; AMP109 (oncology) and AMP110 (corticotropin) advanced non-clinical studies; AMP107 (ophthalmic) continues development for wet AMD/ME.
• Manufacturing: Vertical integration and U.S. footprint remain competitive advantages; IMS facility remediation is impacting specific product releases but not demand.

Market and Competitive Landscape:

• Vaccini faces persistent 340B duplicate discount headwinds estimated at $2.2M for the quarter, with management noting 80% of the issue is addressable by the industry, and they are approaching that limit.
• Lidocaine sales saw a 29% surge due to supplier shortages, creating a backlog of $12.5M at the IMS facility, though resource constraints may limit fulfillment in 2027.
• Glucagon faces intensified competition leading to a 37% sales decline.
• The insulin biosimilar market is crowded with 3-4 existing generic competitors, though management believes there is still room for market entry.
• Ipratropium bromide currently holds a monopoly as the only generic in its market, with expectations for continued market share growth.

Risks and Challenges:

• IMS Facility Remediation: FDA warning letter consequences continue to impact production schedules and margins; full capacity restoration is delayed until mid-2027.
• Pricing Pressure: Duplicate 340B discounts and higher rebates are creating a sustained drag on net pricing that is unlikely to fully recover to historical levels in 2027.
• Supply Chain: Competition for manufacturing resources at the IMS facility poses a risk to fulfilling orders for Lidocaine and other backlog items.
• Regulatory Timelines: Proprietary development programs (e.g., AMP101, AMP109) face typical R&D risks and potential delays, though no specific FDA feedback delays were cited for the recent AMP005/017 filing shifts.

Management Commentary and Tone:

• Management expressed confidence in the record commercial performance and the strength of their differentiated portfolio.
• The tone was cautious yet forward-looking regarding the IMS remediation, emphasizing that operational impacts are distinct from demand issues and that supply of essential medicines is being maintained.
• Management highlighted disciplined capital allocation and the strategic value of their vertically integrated U.S. manufacturing model.
• CFO Bill Peters and CEO Dan Dishner emphasized that the pricing headwinds are easing relative to prior quarters, providing better comps for the upcoming year.

Analyst Questions and Answers:

• Duplicate Discounts: Management confirmed they are approaching the 80% industry resolution threshold but do not expect to exceed it; residual headwinds will persist.
• IMS Impact: Quantified extra remediation expenses at $2-3 million per quarter for the near term, with a return to full capacity expected by mid-2027.
• Glucagon/Lidocaine: Analysts noted supplier shortages boosting Lidocaine; management acknowledged continued demand but warned of resource allocation conflicts due to IMS controls.
• Biosimilar Timing: Clarified that the insulin biosimilar launch is a 2027 event but without a firm Q1 date; emphasized the competitive nature of the GLP-1 space.
• Pricing Recovery: Reiterated that Vaccini pricing will not fully recover to historical levels due to structural 340B issues, despite a 3% price increase taken earlier in the year.

Other Key Points:

• A new proprietary formulation for Primatine Mist (AMP108) with lower global warming potential was introduced to ensure regulatory compliance and extend IP protection.
• Teriparatide, launched in December 2025, contributed significantly to "Other" pharmaceutical sales.
• API sales from the ANP subsidiary also contributed positively to the quarter's total revenue.
• The company is actively reducing the backlog at the IMS facility to capture deferred sales in the coming quarters.